Maha Radhakrishnan
Board Member
Entrada Therapeutics, Inc. (TRDA)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Maha Radhakrishnan
Maha Radhakrishnan is recorded as Board Member at Entrada Therapeutics, Inc. (TRDA). Entrada Therapeutics, Inc. reported in an 8-K filed June 3, 2025 that Maha Radhakrishnan was appointed Class III director, effective June 1, 2025.
“On May 30, 2025, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) expanded the size of the Board from six to seven directors and appointed Maha Radhakrishnan, M.D. to the Board as a Class III director, to serve until the Company’s annual meeting of stockholders to be held in 2027 or until her successor is duly elected and qualified, in each case effective as of June 1, 2025.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2025-06-01–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Entrada Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Kory Wentworth CFO
- Nathan J. Dowden COO
- Bernhardt Zeiher Board Member
- Bernhardt Zeiher, M.D. Board Member
- Kush M. Parmar, M.D., Ph.D. Board Member
- Peter S. Kim Board Member
- Peter S. Kim, Ph.D. Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.